NASD · Healthcare · Biotechnology · USA
Twist Bioscience Corp is a mid cap company (market value between $2 billion and $10 billion) in the Biotechnology industry.
Twist Bioscience develops a DNA synthesis platform that manufactures synthetic DNA on silicon chips for research across healthcare, chemicals, materials, food, and agriculture. The company offers synthetic genes, sequencing tools, oligonucleotide pools, and biopharma services to biotech, pharma, industrial, and academic customers worldwide, enabling efficient drug discovery, diagnostics, and therapeutics development.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Twist Bioscience Corp stock.
Overvalued: intrinsic value $28.39 per share, market price $139.77, margin of safety -392.3% (as of 2026-10-19).
A 4.2x revenue multiple, discounted for its losses, values the shares at $28.39; the price of $139.77 is 392% above that value.
Leak Score: 45/100 on 8 of 12 signals (On Watch).
17 more funds hold it; the full list is part of the paid plan.
91 more in this industry show a wider margin of safety.
TWST is overvalued (as of the 2026-10-19 close). A 4.2x revenue multiple, discounted for its losses, values the shares at $28.39; the price of $139.77 is 392% above that value.
$28.39 per share (as of the 2026-10-19 close), against a market price of $139.77. That is a margin of safety of -392.3%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.
45 out of 100, which we rate "On Watch", on 8 of 12 value investing signals.